Screener
GeneDx Holdings WGS Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by GeneDx Holdings in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: GeneDx Holdings’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001818331-26-000041
| Line item | March 31, 2026 (Unaudited) | December 31, 2025 |
|---|---|---|
| Stockholders’ Equity: | ||
| Preferred Stock, $0.0001 par value: 1,000,000 shares authorized, 0 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | — | — |
| Class A common stock, $0.0001 par value: 1,000,000,000 shares authorized, 29,666,318 and 29,245,296 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 3 | 3 |
| Additional paid-in capital | 1,690,249 | 1,680,738 |
| Accumulated deficit | (1,436,811) | (1,373,495) |
| Accumulated other comprehensive income | 683 | 936 |
| Total stockholders’ equity | 254,124 | 308,182 |
| Total liabilities and stockholders’ equity | $506,301 | $523,710 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is GeneDx Holdings's total equity?
- GeneDx Holdings (WGS) reported total equity of $254.12M in Q1 2026.
- How has GeneDx Holdings's total equity changed year-over-year?
- GeneDx Holdings's total equity decreased by 1.3% year-over-year, from $257.41M to $254.12M.
- What is the long-term trend for GeneDx Holdings's total equity?
- Over 5 years (2020 to 2025), GeneDx Holdings's total equity has grown at a -1.4% compound annual growth rate (CAGR), from -$330.05M to $308.18M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about GeneDx Holdings's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude